(Adding category - Chlamydia Pneumoniae) |
|||
| Line 414: | Line 414: | ||
*Acknowledgement: The study was supported by NIH grant R01DA031006 awarded to David Gilbert. | *Acknowledgement: The study was supported by NIH grant R01DA031006 awarded to David Gilbert. | ||
*Keywords: Cannabis; Marijuana; Negative affect; Nicotine; Smoking; THC; Testing effect; Withdrawal symptoms. | *Keywords: Cannabis; Marijuana; Negative affect; Nicotine; Smoking; THC; Testing effect; Withdrawal symptoms. | ||
<br> | |||
='''Chlamydia Pneumoniae'''= | |||
*Chlamydia pneumoniae is a type of bacteria that can cause respiratory tract infections, such as pneumonia. C. pneumoniae is one cause of community-acquired pneumonia or lung infections developed outside of a healthcare setting. However, not everyone exposed to C. pneumoniae will develop pneumonia. [https://www.cdc.gov/pneumonia/atypical/cpneumoniae/index.html Source: US CDC] | |||
===2013 [https://journals.asm.org/doi/10.1128/cvi.00636-12 Targeting the “Cytokine Storm” for Therapeutic Benefit]=== | |||
*Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila (54) and Chlamydia pneumoniae (55) infection... | |||
*Citation: D'Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., & Clark, G. C. (2013). Targeting the "cytokine storm" for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12 | |||
<br> | <br> | ||
edits